OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

July 13th 2023

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

Dr Johnson on Trastuzumab Plus Paclitaxel in HER2+ Breast Cancer

July 13th 2023

Kai Conrad Cecil Johnson, MD, discusses key invasive disease-free survival findings from the final 10-year analysis of the phase 2 APT trial and HER2DX exploratory analyses in patients with HER2-positive breast cancer.

Dr Matous on Barriers to CAR T-Cell Therapy Administration in Multiple Myeloma

July 13th 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

Dr Lowentritt on the Implications of Data on Real-World ASRI Efficacy in mCSPC

July 13th 2023

Benjamin H. Lowentritt, MD, FACS, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors in patients with mCSPC could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

July 12th 2023

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.

Dr Gastman on Exploratory Biomarker Analysis of the Checkmate76K Trial in Stage IIB/C Melanoma

July 12th 2023

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

Dr Levy on the Correlation Between Upfront NGS and OS Benefit in NSCLC

July 11th 2023

Benjamin Philip Levy, MD, discusses the relationship between upfront next-generation sequencing and survival outcomes in non–small cell lung cancer.

Dr Batchelor on the Rationale for Investigating Tirabrutinib in PCNSL

July 11th 2023

Tracy T. Batchelor, MD, MPH, discusses the rationale for investigating tirabrutinib for the treatment of patients with primary central nervous system lymphoma.

Dr Galsky on Atezolizumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

July 10th 2023

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer

July 10th 2023

Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.

Dr Kilburn on Findings From the FIREFLY-1 Trial of Tovorafenib in Pediatric Low-Grade Glioma

July 10th 2023

Lindsay Kilburn, MD, discusses key efficacy findings from the phase 2 FIREFLY-1 trial of the investigational type II RAF inhibitor tovorafenib (DAY101) in heavily pretreated pediatric patients with low-grade glioma.

Dr Erba on the Initial Safety and Activity of Ziftomenib in AML

July 10th 2023

Harry P Erba, MD, PhD, discusses the safety profile and preliminary activity of the investigational menin inhibitor ziftomenib in acute myeloid leukemia.

Dr Williams on Frontline Niraparib Maintenance Therapy in Ovarian Cancer

July 7th 2023

Heather R. Williams, MD, discusses findings from the phase 3 PRIMA trial in patients with ovarian cancer.

Dr Santos on Frontline Therapies in ALK+ NSCLC

July 7th 2023

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.

Dr. Yuan on Ongoing Research in Patients With TNBC According to Pathologic Response

July 7th 2023

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

Dr Simon on PD-L1 Inhibitors in NSCLC

July 6th 2023

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.

Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC

July 6th 2023

Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Dr Gehrig on the Use of Genetic Testing in Endometrial Cancer

July 6th 2023

Paola Gehrig, MD, discusses the optimal use and timing of genetic testing in endometrial cancer.

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

July 6th 2023

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

July 5th 2023

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.